Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Clinical implications of imlifidase interference in antibody screening and transfusion management
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani +2 more
wiley +1 more source
EGFR-Targeting IgG1 Antibody Enhances NK Cell-Mediated Tumor Killing in KRAS-Mutant Pancreatic Cancer. [PDF]
Xiao R +10 more
europepmc +1 more source
Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies. [PDF]
Han L, Jiang H, Chiu ML.
europepmc +1 more source
Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa. [PDF]
Strizhakova O +7 more
europepmc +1 more source
Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide. [PDF]
Dobson LJ +6 more
europepmc +1 more source
Erratum: AGR2 promotes the proliferation, migration and regulates epithelial-mesenchymal transition in salivary adenoid cystic carcinoma. [PDF]
Ma SR +7 more
europepmc +1 more source
2D NMR assessment of structural consistency and functional relationships in monoclonal antibodies. [PDF]
Wang L +5 more
europepmc +1 more source

